Background
Candida is a leading cause of infection in infants on extracorporeal membrane oxygenation (ECMO). Optimal micafungin dosing is unknown in this population because ECMO can alter drug pharmacokinetics (PK).
Methods
To characterize micafungin PK and safety in infants on ECMO, we conducted an open label PK trial. Infants on ECMO either received IV micafungin 4 mg/kg/day for invasive candidiasis prophylaxis, or 8 mg/kg/day when a fungal infection was suspected or confirmed. We collected plasma samples after single and multiple micafungin doses. We defined the therapeutic target as the adult exposure associated with efficacy in Phase III trials, and the prophylactic target as one-half of the therapeutic target.
Results
We enrolled 12 infants (124 samples) with a median age of 59 days. Using a 1-compartment model, median weight-normalized volume of distribution and clearance were 0.64 L/kg and 0.041 L/kg/h, respectively. Dose-exposure simulations revealed that doses of 2.5 and 5 mg/kg/day matched exposure targets for prophylaxis and treatment of invasive candidiasis, respectively. We did not observe any drug-related adverse events.
Conclusions
In infants on ECMO, micafungin volume of distribution was higher and clearance was in the upper range of previously published values for infants not on ECMO. Based on these data, we recommend dosing of 2.5 and 5 mg/kg/day for prophylaxis and treatment of invasive candidiasis, respectively, to match adult exposure proven effective against Candida spp.